Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies
Modern treatment modalities in hematology have improved clinical outcomes of patients with hematological malignancies. Nevertheless, many new or conventional anticancer drugs affect the cardiovascular system, resulting in various cardiac disorders, including left ventricular dysfunction, heart failu...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/15/8/1007 |
| _version_ | 1797431808921436160 |
|---|---|
| author | Anastasia Stella Perpinia Nikolaos Kadoglou Maria Vardaka Georgios Gkortzolidis Apostolos Karavidas Theodoros Marinakis Chrysostomi Papachrysostomou Panagiotis Makaronis Charikleia Vlachou Marina Mantzourani Dimitrios Farmakis Konstantinos Konstantopoulos |
| author_facet | Anastasia Stella Perpinia Nikolaos Kadoglou Maria Vardaka Georgios Gkortzolidis Apostolos Karavidas Theodoros Marinakis Chrysostomi Papachrysostomou Panagiotis Makaronis Charikleia Vlachou Marina Mantzourani Dimitrios Farmakis Konstantinos Konstantopoulos |
| author_sort | Anastasia Stella Perpinia |
| collection | DOAJ |
| description | Modern treatment modalities in hematology have improved clinical outcomes of patients with hematological malignancies. Nevertheless, many new or conventional anticancer drugs affect the cardiovascular system, resulting in various cardiac disorders, including left ventricular dysfunction, heart failure, arterial hypertension, myocardial ischemia, cardiac rhythm disturbances, and QTc prolongation on electrocardiograms. As these complications may jeopardize the significantly improved outcome of modern anticancer therapies, it is crucial to become familiar with all aspects of cardiotoxicity and provide appropriate care promptly to these patients. In addition, established and new drugs contribute to primary and secondary cardiovascular diseases prevention. This review focuses on the clinical manifestations, preventive strategies, and pharmaceutical management of cardiotoxicity in patients with hematologic malignancies undergoing anticancer drug therapy or hematopoietic stem cell transplantation. |
| first_indexed | 2024-03-09T09:50:40Z |
| format | Article |
| id | doaj.art-2739d523aa9648ef95913a3410278e51 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-09T09:50:40Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-2739d523aa9648ef95913a3410278e512023-12-02T00:09:06ZengMDPI AGPharmaceuticals1424-82472022-08-01158100710.3390/ph15081007Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological MalignanciesAnastasia Stella Perpinia0Nikolaos Kadoglou1Maria Vardaka2Georgios Gkortzolidis3Apostolos Karavidas4Theodoros Marinakis5Chrysostomi Papachrysostomou6Panagiotis Makaronis7Charikleia Vlachou8Marina Mantzourani9Dimitrios Farmakis10Konstantinos Konstantopoulos11Department of Cardiology, “G. Gennimatas” General Hospital, 11527 Athens, GreeceMedical School, University of Cyprus, Nicosia 2029, CyprusDepartment of Hematology, “G. Gennimatas” General Hospital, 11527 Athens, GreeceDepartment of Hematology, “G. Gennimatas” General Hospital, 11527 Athens, GreeceDepartment of Cardiology, “G. Gennimatas” General Hospital, 11527 Athens, GreeceDepartment of Hematology, “G. Gennimatas” General Hospital, 11527 Athens, GreeceDepartment of Cardiology, “G. Gennimatas” General Hospital, 11527 Athens, GreeceDepartment of Cardiology, “G. Gennimatas” General Hospital, 11527 Athens, GreeceDepartment of Hematology, “G. Gennimatas” General Hospital, 11527 Athens, GreeceFirst Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, “Laiko” General Hospital, 11527 Athens, GreeceMedical School, University of Cyprus, Nicosia 2029, CyprusDepartment of Hematology, Medical School, National and Kapodistrian University of Athens, “Laiko” General Hospital, 11527 Athens, GreeceModern treatment modalities in hematology have improved clinical outcomes of patients with hematological malignancies. Nevertheless, many new or conventional anticancer drugs affect the cardiovascular system, resulting in various cardiac disorders, including left ventricular dysfunction, heart failure, arterial hypertension, myocardial ischemia, cardiac rhythm disturbances, and QTc prolongation on electrocardiograms. As these complications may jeopardize the significantly improved outcome of modern anticancer therapies, it is crucial to become familiar with all aspects of cardiotoxicity and provide appropriate care promptly to these patients. In addition, established and new drugs contribute to primary and secondary cardiovascular diseases prevention. This review focuses on the clinical manifestations, preventive strategies, and pharmaceutical management of cardiotoxicity in patients with hematologic malignancies undergoing anticancer drug therapy or hematopoietic stem cell transplantation.https://www.mdpi.com/1424-8247/15/8/1007leukemialymphomacardiotoxicityheart failureanthracyclinesanticancer targeted therapies |
| spellingShingle | Anastasia Stella Perpinia Nikolaos Kadoglou Maria Vardaka Georgios Gkortzolidis Apostolos Karavidas Theodoros Marinakis Chrysostomi Papachrysostomou Panagiotis Makaronis Charikleia Vlachou Marina Mantzourani Dimitrios Farmakis Konstantinos Konstantopoulos Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies Pharmaceuticals leukemia lymphoma cardiotoxicity heart failure anthracyclines anticancer targeted therapies |
| title | Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies |
| title_full | Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies |
| title_fullStr | Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies |
| title_full_unstemmed | Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies |
| title_short | Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies |
| title_sort | pharmaceutical prevention and management of cardiotoxicity in hematological malignancies |
| topic | leukemia lymphoma cardiotoxicity heart failure anthracyclines anticancer targeted therapies |
| url | https://www.mdpi.com/1424-8247/15/8/1007 |
| work_keys_str_mv | AT anastasiastellaperpinia pharmaceuticalpreventionandmanagementofcardiotoxicityinhematologicalmalignancies AT nikolaoskadoglou pharmaceuticalpreventionandmanagementofcardiotoxicityinhematologicalmalignancies AT mariavardaka pharmaceuticalpreventionandmanagementofcardiotoxicityinhematologicalmalignancies AT georgiosgkortzolidis pharmaceuticalpreventionandmanagementofcardiotoxicityinhematologicalmalignancies AT apostoloskaravidas pharmaceuticalpreventionandmanagementofcardiotoxicityinhematologicalmalignancies AT theodorosmarinakis pharmaceuticalpreventionandmanagementofcardiotoxicityinhematologicalmalignancies AT chrysostomipapachrysostomou pharmaceuticalpreventionandmanagementofcardiotoxicityinhematologicalmalignancies AT panagiotismakaronis pharmaceuticalpreventionandmanagementofcardiotoxicityinhematologicalmalignancies AT charikleiavlachou pharmaceuticalpreventionandmanagementofcardiotoxicityinhematologicalmalignancies AT marinamantzourani pharmaceuticalpreventionandmanagementofcardiotoxicityinhematologicalmalignancies AT dimitriosfarmakis pharmaceuticalpreventionandmanagementofcardiotoxicityinhematologicalmalignancies AT konstantinoskonstantopoulos pharmaceuticalpreventionandmanagementofcardiotoxicityinhematologicalmalignancies |